Matsuda C, et al. - Experts evaluated the superiority of 1-year adjuvant treatment with oral tegafur-uracil (UFT) to surgery alone for stage II colon cancer in the SACURA trial, a randomised controlled study. The median follow-up was 69.5 months, 66 years was the median age and for stage IIA/IIB/IIC, the distribution was 84%/13%/3%. As per data, in stage II colon cancer, they did not note the superiority of 1-year adjuvant UFT over surgery alone. UFT did not benefit the patients with risk factors for recurrence. Authors saw a failure of subgroup analysis to disclose superiority in prognosis of adding UFT to the patients with risk factors for recurrence.